Glypican 2

Glypican 2

Glypican 2 Informations sur la molécule

Molecule Name
Glypican-2
Alias de la molécule
Glypican 2,GPC2
Drug Development Progress
Nombre de médicaments cliniques2
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 1 Clinical
Alias de la cible
Cerebroglycan,Glypican Proteoglycan 2, Cerebroglycan Proteoglycan
Contexte de la molécule
Glypican 2 (GPC2), also known cerebroglycan, is a glycophosphatidylinositol-linked integral membrane heparan sulfate proteoglycan found in the developing nervous system. Cerebroglycan participates in cell adhesion and is thought to regulate the growth and guidance of axons. Cerebroglycan has especially high affinity for laminin-1. GPC2 silencing inactivates Wnt/β-catenin signaling and reduces the expression of N-Myc, an oncogenic driver of neuroblastoma tumorigenesis. Immunotoxins and chimeric antigen receptor (CAR) T cells targeting GPC2 inhibit neuroblastoma growth in mouse models. A GPC3 specific antibody drug conjugate (ADC) can also inhibit neuroblastoma cell proliferation.

Glypican 2 Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
anti-glypican-2 CAR T-cell therapy (Childrens Hospital of Philadelphia/Kite Pharma)Phase 1 ClinicalChildrens Hospital of Philadelphia
Rhabdomyosarcoma; Small Cell Lung Carcinoma; Urinary Bladder Neoplasms; Neuroblastoma
Details
GPC2 CAR-T cell therapy(Childrens Hospital of Philadelphia/Tmunity Therapeutics)TmGPC2-01-CAR-TPhase 1 ClinicalChildrens Hospital of Philadelphia
Small Cell Lung Carcinoma; Urinary Bladder Neoplasms; Neuroblastoma
Details